Shopping Cart 0
Cart Subtotal
AED 0

Immunovia AB (IMMNOV) - Medical Equipment - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Immunovia AB (Immunovia) is a molecular diagnostics company that offers clinical testing for early diagnosis of pancreatic cancer. The company develops IMMray, a technology platform based on antibody microarray analysis, which can be used in the early diagnosis of cancer, predicting disease progression, and monitoring the therapeutic responsiveness of cancers. Immunovia's IMMray can also be used for biomarker discovery through its discovery tool for proteome scanning. The company also provides IMMray PanCan-d, a blood-based test for the detection of pancreatic cancer. Its therapeutic areas include cancer and autoimmune diseases such as systemic lupus erythematosus. The company collaborates with various cancer centers for conducting clinical evidence studies. Immunovia is headquartered in Lund, Sweden.

Immunovia AB (IMMNOV)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Immunovia AB, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Immunovia AB, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Immunovia AB, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Immunovia AB, Medical Equipment, Deals By Market, 2012 to YTD 2018 9

Immunovia AB, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Immunovia AB, Medical Equipment, Deal Details 11

Partnerships 11

Immunovia Enters into Research Collaboration Agreement with Linkoping University 11

Immunovia Enters into Agreement with Lund University Diabetes Centre 12

Immunovia Enters into Agreement with University of Michigan Comprehensive Cancer Center 13

Immunovia to Enter into Agreement with National Cancer Institute 14

Immunovia Enters into Agreement with Ramon y Cajal Institute for Health Research 15

Immunovia Enters into Agreement for IMMray 16

Immunovia Partners with Mount Sinai Health System 17

Immunovia Enters into Agreement with University of Liverpool 18

Immunovia Partners with OHSU Knight Cancer Institute 19

Equity Offering 20

Immunovia Raises USD37.3 Million in Private Placement of Shares 20

Immunovia Raises USD3.4 Million in Rights Offering of Shares 22

Immunovia Prices Private Placement of Shares for USD22.3 Million 24

Immunovia Plans to Raise Funds in Public Offering of Shares 25

Immunovia Raises USD7 Million in IPO 26

Immunovia AB-Key Competitors 27

Immunovia AB-Key Employees 28

Immunovia AB-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Financial Announcements 30

Aug 24, 2018: Immunovia interim report, january-june 2018 30

Apr 27, 2018: Immunovia Interim report, January-March 2018 31

Feb 15, 2018: Immunovia Full Year report, January-December 2017 32

Nov 10, 2017: Immunovia Interim report, January-September 2017 33

Aug 23, 2017: Immunovia Interim report January-June 2017 34

Apr 20, 2017: Immunovia Interim report, January-March 2017 35

Feb 15, 2017: Immunovia Financial Statement 2016 36

Corporate Communications 37

Jul 17, 2017: Leading pancreatic cancer expert on early symptoms Professor Stephen Pereira at University College London joins Immunovia's Scientific Advisory Board 37

Legal and Regulatory 38

Jun 28, 2017: Immunovia Establishes US Headquarters, Including CLIA Reference Laboratory, in Boston 38

Product News 39

Sep 17, 2018: New blood test detects early stage pancreatic cancer 39

Jun 21, 2017: Immunovia's IMMray presents biomarkers that differentiates Rheumatoid Arthritis from other autoimmune diseases with 89% accuracy 40

Mar 31, 2017: Edison Issues Update on Immunovia (IMMUNOV) 41

Other Significant Developments 42

Aug 09, 2018: Immunovia's blood-based IMMray biomarker array provides highly accurate diagnosis of non-small cell lung cancer in a new collaborative study 42

Appendix 43

Methodology 43

About GlobalData 43

Contact Us 43

Disclaimer 43


List Of Figure

List of Figures

Immunovia AB, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Immunovia AB, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Immunovia AB, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Immunovia AB, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Immunovia AB, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Immunovia AB, Medical Equipment, Deals by Type, 2012 to YTD 2018 7

Immunovia AB, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Immunovia AB, Medical Equipment, Deals by Market, 2012 to YTD 2018 9


List Of Table

List of Tables

Immunovia AB, Medical Equipment, Key Facts 2

Immunovia AB, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Immunovia AB, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Immunovia AB, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Immunovia AB, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Immunovia AB, Deals By Market, 2012 to YTD 2018 9

Immunovia AB, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Immunovia Enters into Research Collaboration Agreement with Linkoping University 11

Immunovia Enters into Agreement with Lund University Diabetes Centre 12

Immunovia Enters into Agreement with University of Michigan Comprehensive Cancer Center 13

Immunovia to Enter into Agreement with National Cancer Institute 14

Immunovia Enters into Agreement with Ramon y Cajal Institute for Health Research 15

Immunovia Enters into Agreement for IMMray 16

Immunovia Partners with Mount Sinai Health System 17

Immunovia Enters into Agreement with University of Liverpool 18

Immunovia Partners with OHSU Knight Cancer Institute 19

Immunovia Raises USD37.3 Million in Private Placement of Shares 20

Immunovia Raises USD3.4 Million in Rights Offering of Shares 22

Immunovia Prices Private Placement of Shares for USD22.3 Million 24

Immunovia Plans to Raise Funds in Public Offering of Shares 25

Immunovia Raises USD7 Million in IPO 26

Immunovia AB, Key Competitors 27

Immunovia AB, Key Employees 28

Immunovia AB, Subsidiaries 29

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Immunovia AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.